Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transfusion savings in heart surgery: EPO and ScvO2-optimized strategy vs standard care
2019-000401-76Phase 3Completed
- Sponsor
- CHU Montpellier
- Start
- Apr 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of epoetin alfa in heart failure (HF) and cardiac surgery (2 arms), sponsored by CHU Montpellier. Primary endpoint: Incidence of patients transfused during hospital stay after cardiac surgery. Started Apr 2019; status: completed.
02
Drugs
epoetin alfa
03
Conditions
heart failure (HF)cardiac surgery
Beyond the preview
Go deeper on 2019-000401-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000401-76.